Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 51,513
  • Shares Outstanding, K 29,269
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,850 K
  • EBIT $ -30 M
  • EBITDA $ -30 M
  • 60-Month Beta 1.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.72

Options Overview Details

View History
  • Implied Volatility 343.51% (-217.84%)
  • Historical Volatility 128.73%
  • IV Percentile 63%
  • IV Rank 28.36%
  • IV High 1,160.30% on 08/04/25
  • IV Low 20.18% on 01/06/26
  • Expected Move (DTE 1) 0.3145 (17.72%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 149
  • Volume Avg (30-Day) 1,046
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 21,435
  • Open Int (30-Day) 16,279
  • Expected Range 1.4605 to 2.0895

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.43
  • Growth Rate Est. (year over year) +232,425.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5407 +15.86%
on 04/10/26
3.0288 -41.07%
on 03/17/26
-1.0450 (-36.93%)
since 03/16/26
3-Month
1.5407 +15.86%
on 04/10/26
3.1887 -44.02%
on 01/22/26
-1.1050 (-38.24%)
since 01/16/26
52-Week
1.1900 +50.00%
on 04/17/25
5.5000 -67.55%
on 11/28/25
+0.5250 (+41.67%)
since 04/16/25

Most Recent Stories

More News
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Financing secures path to first NDA submission for buntanetap 6-Month symptomatic data readout anticipated Q1 2027 Alzheimer’s disease Phase 3 trial 75% enrolled Parkinson's disease open-label...

ANVS : 1.7800 (+1.14%)
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.7800 (+1.14%)
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.7800 (+1.14%)
Annovis Publishes Historical Review of Buntanetap in The Scientist

MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.7800 (+1.14%)
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.7800 (+1.14%)
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.7800 (+1.14%)
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.7800 (+1.14%)
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ANVS : 1.7800 (+1.14%)
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis...

ANVS : 1.7800 (+1.14%)
Annovis to Host Corporate Update Webinar on January 28, 2026

MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

ANVS : 1.7800 (+1.14%)

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 1.8983
2nd Resistance Point 1.8467
1st Resistance Point 1.8033
Last Price 1.7800
1st Support Level 1.7083
2nd Support Level 1.6567
3rd Support Level 1.6133

See More

52-Week High 5.5000
Fibonacci 61.8% 3.8536
Fibonacci 50% 3.3450
Fibonacci 38.2% 2.8364
Last Price 1.7800
52-Week Low 1.1900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.